Here's What Key Metrics Tell Us About Penumbra (PEN) Q4 Earnings

Core Insights - Penumbra reported revenue of $315.52 million for Q4 2024, marking a year-over-year increase of 10.8% and exceeding the Zacks Consensus Estimate by 1.07% [1] - The company's EPS for the same quarter was $0.97, up from $0.76 a year ago, representing a surprise of 6.59% over the consensus estimate of $0.91 [1] Revenue Breakdown - International revenue was $67.60 million, which fell short of the average estimate of $75.61 million, reflecting a year-over-year decline of 16.5% [4] - U.S. revenue reached $247.92 million, surpassing the average estimate of $235.65 million, with a year-over-year increase of 21.7% [4] - Revenue from Embolization and Access was $95.39 million, below the average estimate of $99.71 million [4] - Revenue from Thrombectomy was $220.13 million, slightly above the average estimate of $212.35 million [4] Stock Performance - Over the past month, Penumbra's shares returned +1.9%, compared to a +4.7% change in the Zacks S&P 500 composite [3] - The stock currently holds a Zacks Rank 3 (Hold), indicating expected performance in line with the broader market [3]